Welcome to our dedicated page for Elutia news (Ticker: ELUT), a resource for investors and traders seeking the latest updates and insights on Elutia stock.
Elutia Inc. develops and commercializes drug-eluting biomatrix products designed to improve compatibility between implanted medical devices and patients. Company news commonly covers financial results, product revenue from SimpliDerm and cardiovascular products, and development updates for NXT-41 and NXT-41x biomatrix technologies used in surgical reconstruction and related applications.
Recurring updates also include regulatory-process disclosures, commercial planning for plastic and reconstructive surgery, management presentations, equity compensation actions, and Nasdaq listing-compliance matters for Elutia's Class A common stock. The company's communications often connect its biomatrix platform with implant-based breast reconstruction, post-surgical infection reduction, and broader surgical-support use cases.
Elutia (NASDAQ: ELUT) reported strong Q2 2025 results, driven by its flagship EluPro™ antibiotic bioenvelope. EluPro's Q2 revenue surged 49% sequentially, with BioEnvelope revenue reaching $3.5 million, up 33% year-over-year. The company has achieved significant market penetration with over 160 VAC-approved centers and strategic partnerships with Boston Scientific.
Total Q2 2025 revenue was $6.3 million, with gross margin improving to 48.8%. The company reported a net loss of $9.6 million. Elutia is advancing its pipeline with NXT-41, a next-generation drug-eluting biomatrix for breast reconstruction, targeting FDA clearance in 2H26. The company expects BioEnvelope sales to approach a $20 million annualized run rate by year-end.
Elutia (Nasdaq: ELUT), a drug-eluting biomatrix technologies company, has scheduled its second quarter 2025 financial results release for Thursday, August 14, 2025, after market close.
The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day. Management will be available to discuss the results, with both domestic and international dial-in numbers provided for investor participation.
[]Elutia (Nasdaq: ELUT) announced that its Chief Scientific Officer, Dr. Michelle LeRoux Williams, has received the Medical Device Innovator Award from the Washington Business Journal. The recognition highlights her leadership in developing EluPro™, the first FDA-cleared antibiotic-eluting bioenvelope for cardiac implantable electronic devices (CIEDs).
EluPro, which received FDA clearance and launched commercially in January 2025, combines a regenerative biomatrix with antibiotics rifampin and minocycline. The technology addresses complications in CIEDs, with the market potential of over 600,000 annual CIED implants in the U.S., where complications occur in 5-7% of cases.
Elutia (NASDAQ: ELUT) announced new study results supporting the effectiveness of its EluPro BioEnvelope, an antibiotic-eluting device for cardiac implantable electronic devices (CIEDs). The study, published in the Journal of Functional Biomaterials, demonstrated that EluPro's biomatrix effectively controls inflammation and supports vascularization.
Research from the Cumming School of Medicine showed that EluPro stimulates early proangiogenic signals and reduces fibrosis over time. The study revealed significantly higher levels of growth and wound healing factors compared to controls (p0.001), with long-term animal studies demonstrating improved blood vessel formation and reduced inflammation over a .
EluPro, which received FDA clearance and was commercially launched in the United States in January 2025, is the first and only antibiotic-eluting bioenvelope approved for use with CIEDs and neurostimulators.
Elutia (Nasdaq: ELUT) has received dual honors at the 2025 Medical Device Network Excellence Awards for Innovation and Product Launches, recognizing their EluPro™ Antibiotic-Eluting BioEnvelope technology. EluPro, launched in January 2025, is designed to protect cardiac implantable electronic devices and neurostimulators.
The product has shown strong commercial performance with 84% sequential sales growth in Q1 2025 and drove a 31% year-over-year increase in BioEnvelope sales. EluPro has secured approvals from 150 hospital value analysis committees and partnerships with seven major group purchasing organizations.
The technology addresses a significant market need, with over 600,000 CIEDs implanted annually in the U.S. and complications occurring in 5-7% of cases.
Elutia (NASDAQ: ELUT) announced the transition to direct distribution of its cardiovascular product portfolio, ending its distribution agreement with LeMaitre Vascular. The company has appointed Dwayne Montgomery as Head of Cardiovascular and recruited 26 independent sales representatives dedicated to the cardiovascular line.
The cardiovascular portfolio, which includes ProxiCor®, VasCure®, and Tyke®, generated $2.9 million in revenue (12% of total) in 2024 and is expected to achieve 80% gross margins. These regenerative biomatrix products are designed for various cardiac and vascular repairs, offering advantages over synthetic alternatives by promoting healthy immune responses.
The strategic move aims to enhance top-line growth, improve gross margins and profitability, and provide greater strategic control over sales operations.
Elutia (Nasdaq: ELUT), a company specializing in drug-eluting biomatrix technologies, has scheduled the release of its Q1 2025 financial results for Thursday, May 8, 2025, after market close. The management team will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day. U.S. investors can join via 877-407-8029, while international investors can dial 201-689-8029 using Conference ID 13753035. A live and archived webcast will be available on the company's investor relations website.
Elutia (Nasdaq: ELUT), a leader in drug-eluting biomatrix technologies, has announced its participation in Chardan's Trending Issues in Drug Development Conference Series. The company's Chief Scientific Officer, Dr. Michelle LeRoux Williams, will join a fireside chat discussion focused on 'Data & Regulatory Catalysts – Navigating an Evolving Landscape' on Tuesday, April 29, 2025, at 11:00 a.m. ET.
The virtual event will be accessible to investors and interested parties through a live webcast, with an archived version available afterward on the company's investor relations website at investors.elutia.com.